Statistically significant clinical phase III results of Lu AA21004
14 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004...
List view / Grid view
14 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004...
14 May 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the company will present 18 abstracts on ORENCIA®...
14 May 2012 | By Biogen Idec
Two new dosing innovations designed to help patients receiving once-a-week AVONEX...
14 May 2012 | By University of Dundee
The consortium includes six companies & will provide core support of £14.4 million...
14 May 2012 | By B&W Tek, Inc.
B&W Tek, Inc., is proud to introduce the future of miniature spectrometers...
11 May 2012 | By Catalent Pharma Solutions
Thomas Feinberg, will deliver an update on the PODP working group...
11 May 2012 | By Gilead Sciences
Final FDA decision on the Quad anticipated late summer...
11 May 2012 | By GlaxoSmithKline
The FDA has approved the New Drug Application for Fabior (tazarotene) Foam...
10 May 2012 | By Ballou PR
Company combines expertise in assay design with its powerful HTRF® technology...
10 May 2012 | By Novartis
Research on Lucentis® is highlighted in more than 200 abstracts this week at the 2012 ARVO annual meeting....
10 May 2012 | By Pfizer
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with David Simmons...
10 May 2012 | By Gilead Sciences
Vote to support approval of once-daily oral Truvada®...
10 May 2012 | By Bristol-Myers Squibb Company
Doug Manion to will make a formal presentation...
9 May 2012 | By Patheon
Patheon continues to implement its corporate transformation strategy across its commercial and pharmaceutical development services...
9 May 2012 | By BASF
BASF has announced the acquisition of Equateq Ltd...